Nanobiotix (NBTX NASDAQ) stock market data APIs
$22.3967
0.03(0.1%)
as of December 16, 2025
Try our APIs with
free plan!
Nanobiotix Financial Data Overview
Price chart is built with
Anychart
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Prev. Close
22.3967
Open
22.4267
High
22.7647
Low
22.1766
52 wk Range
2.82-30.35
Market Cap
1 077 M
Shares Outstanding
48 215 K
Revenue
10 159 K
EPS
0
Beta
0.476
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Nanobiotix data using free add-ons & libraries
Get Nanobiotix Fundamental Data
Nanobiotix Fundamental data includes:
- Net Revenue: 10 159 K
- EBITDA: -43 844 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-20
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Nanobiotix News
New
NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
PARIS and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering ph...
NANOBIOTIX va intégrer les indices CAC Mid 60 et SBF 120 d’Euronext Paris
PARIS et CAMBRIDGE, Mass., 15 déc. 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO – NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement ...
Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook
Financial foundation toward self-sustained long-term growth established with the closing with HealthCare Royalty (“HCRx”) of a non-dilutive royalty financing valued up to $71 millionProgress in th...
NANOBIOTIX fait le point sur sa trésorerie et son activité opérationnelle du troisième trimestre 2025 et partage des perspectives cliniques pour 2026
Base financière posée dans la perspective d’une autonomie financière et d’une croissance à long-terme via la finalisation de l’accord de financement non-dilutif de partage de redevances (roy...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
